BNTX:NASDAQ
BioNTech SE - ADR
98,51 US$
arrow_upward
+1,66%(+1,61) 1D
5 tet, 1:54:42 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BNTX...
Hap
96,74 US$
I lartë
98,78 US$
I ulët
95,20 US$
Kapitalizimi i tregut
24,75 mld
Vëllimi mesatar
1,10 mln
Vëllimi
448,06 mijë
Maksimumi 52-javor
123,98 US$
Minimumi 52-javor
79,52 US$
Fitimet për aksion
-7,55 US$
Beta
1,22
Aksionet në qarkullim
251,20 mln
Numri i punonjësve
8 mijë
Hap
96,74 US$
I lartë
98,78 US$
I ulët
95,20 US$
Kapitalizimi i tregut
24,75 mld
Vëllimi mesatar
1,10 mln
Vëllimi
448,06 mijë
Maksimumi 52-javor
123,98 US$
Minimumi 52-javor
79,52 US$
Fitimet për aksion
-7,55 US$
Beta
1,22
Aksionet në qarkullim
251,20 mln
Numri i punonjësve
8 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
AD HOC NEWS
·
1 orë më parë
BioNTech stock draws Moderate Buy consensus at USD 126 target
AD HOC NEWS
·
6 orë më parë
BioNTech CEO Offloads 100,000 Shares as Founders' Exit Talks Turn Testy
AD HOC NEWS
·
10 orë më parë
Berenberg raises target for BioNTech stock from USD 132 to USD 140
AD HOC NEWS
·
1 ditë më parë
BioNTech stock faces a 59.5 percent Q2 revenue drop
Profili
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Rreth BioNTech SE - ADR